|
Author Archive: AZBio
Arizona’s Biotech Community Connects with the World at #JPM18
Arizona’s biotech community will be telling its story at the largest annual convergence of life science innovators and investors during JPM18.Continue reading
ASU awarded $6.4M grant to test preventive cancer vaccine for dogs
Grant will support the largest interventional canine clinical trial ever conducted.Continue reading
Applications are open for first class of TGen Bioscience Leadership Academy
New high school program joins successful Helios Scholars at TGen in preparing Arizona students for high-tech biomedical careersContinue reading
NINDS Awards $150,000 Grant to NuvOx Pharma for Development of Field-ready Syringe for Oxygen Delivery Drug.
NuvOx Pharma, a clinical stage biotechnology company based in Tucson, Arizona, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may allow quick preparation of an investigational drug for oxygen delivery.Continue reading
HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research ProgramsContinue reading
Three Arizona Biotech Companies Win Fall Arizona Innovation Challenge
The Fall 2017 round of the Arizona Innovation Challenge (AIC) has concluded as the Arizona Commerce Authority (ACA) today announced six awardees in its semi-annual business plan competition including Arizona biotech companies Life365, Inc. GT Medical Technologies, and Resonea.
C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)
Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDSfor exploratory use represents a major milestone for the PRO Consortium and specifically for the Depression Working Group, and is the culmination of a multi-year collaboration between FDA’s Center for Drug Evaluation and Research (CDER) and the PRO Consortium.Continue reading